Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer
Kartik Sehgal, Anushi Bulumulle, Heather Brody, Ritu R. Gill, Shravanti Macherla, Aleksandra Qilleri, Danielle C. McDonald, Cynthia R. Cherry, Meghan Shea, Mark S. Huberman, Paul A. VanderLaan, Glen J. Weiss, Paul R. Walker, Daniel B. Costa, Deepa Rangachari
Topics & Concepts
MedicinePembrolizumabHazard ratioInternal medicineConfidence intervalLung cancerOncologyDurvalumabAdverse effectRetrospective cohort studyCancerImmunotherapyCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations